Akademik Veri Yönetim Sistemi
Comprehensive medicine, cilt.15, sa.1, ss.44-49, 2023 (Hakemli Dergi)
Objective: No specific treatment has been reported for coronavirus disease-2019 (COVID-19). The use of broad-spectrum antivirals has come up again for COVID-19. We aimed to investigate the effect of favipiravir (FPV) onset time on intensive care hospitalization rate and progression in the treatment of COVID-19. Materials and Methods: The data of 90 patients who used favipiravir in the isolation wards and intensive care units of our hospital in March, April, and May were reviewed retrospectively. According to symptom onset time, FPV onset time, hospitalization time in the intensive care unit, exitus time, recovery, and discharge time were recorded. In addition, as a laboratory, D-dimer, ferritin, C-reactive protein (CRP), white blood cell, lymphocyte, and fibrinogen counts were recorded. Using these data, the effect of FPV onset time on the progression of the disease was investigated. Results: As a result of the statistical analysis, the mean age of those who were exitus (ex) was significantly higher than those who survived. The PCR positivity of the patients who were exitus was found to be significantly less than the survivors. The difference in CRP level increases as the time taken for the onset of FPV increases. If FPV is started late, the length of stay in the intensive care unit increases. Conclusion: Nowadays, when the COVID-19 pandemic is thought to be over, there is still no effective treatment for COVID-19 in the world. The fact that FPV reduces the length of hospital stay has provided ease of treatment in pandemic days when the number of hospital beds is important. Therefore, more studies on FPV are needed.